Sanofi Highlights Results from the P-II Trial of Rilzabrutinib for the Treatement of Chronic Spontaneous Urticaria (CSU) at AAAAI 2024
Shots:
- The dose-ranging P-II (RILECSU) trial assesses rilzabrutinib's (400mg, QPM, BID, TID) safety & efficacy vs PBO in moderate-to-severe CSU adults (n=160) symptomatic even after H1 antihistamine use, naïve to or are inadequate responders to omalizumab (ITT population). The P-III study is anticipated in 2024
- The study in the ITT population revealed that rilzabrutinib (400mg, TID) showed reduction in weekly itch severity score (ISS7) (LSM: -9.58 vs -6.31) with favorable changes in wk.1, reduction in weekly urticaria activity score (UAS7) (LSM -17.95 vs -11.20), & reduction in weekly hives severity score (HSS7) (LSM -8.31 vs -4.89) from baseline to wk.12
- Rilzabrutinib (oral) targets BTK to minimize the risk of off-target side effects
Ref: Globe Newswire | Image: Sanofi
Related News:- Sanofi Publishes Results of Rilzabrutinib in P-I/II Study for the Treatment of Immune Thrombocytopenia in NEJM
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
